Overweight Individuals with Health Conditions: People with a BMI of 27 or higher who also have weight-related health issues, such as type 2 diabetes, hypertension, or high cholesterol, can benefit from GLP-1 shots
Advocacy, careful patient selection, and evidence-based practice will be essential to ensure these therapies are used safely, effectively, and equitably in everyday patient care settings
A 4-week supply to gradually increase metabolic support
Glucagon-like peptide-1: a new potential regulator for mesenchymal stem cells in the treatment of type 2 diabetes mellitus and its complication
Mounjaros manufacturer, Eli Lilly, submitted the motion to create this multidistrict litigation (MDL)
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity